Neurobell

What Neurobell does

NeuroBell Ltd. is an Irish medical device company developing NeuroBell Luna, a portable, pocket-sized, wireless EEG monitor with built-in AI-powered automated seizure detection intended for use in neonatal intensive care units (NICUs). The device is an 8-channel, battery-powered, WiFi-enabled system with an ACNS-compliant montage and 10-20 EEG placement for neonates, featuring a simplified two-button setup so non-specialist NICU staff can deploy it. A cloud-connected review and storage layer supports remote interpretation by clinicians. The product addresses a clinical need in which neonatal seizures — a common manifestation of newborn brain injury — frequently have no visible physical signs and currently require specialist neurological monitoring that is often unavailable, causing delays in diagnosis and treatment.

The underlying technology combines custom hardware (the portable EEG monitor), proprietary deep learning software for automated seizure detection, and clinically-annotated EEG datasets accumulated since 2015 at the INFANT Research Centre, University College Cork. NeuroBell's IP is patent-pending, and the company operates an ISO 13485-certified quality management system for medical device design, development, and manufacturing. Founded as a UCC spin-out in 2023, NeuroBell is currently in clinical validation with hospital partners in Ireland (Cork University Hospital) and the United States (Parkview Health, Texas Children's Hospital), working toward FDA clearance and a US market launch targeted for 2026, with European commercialization expected to follow.

Commercially, NeuroBell plans a hardware-led, direct enterprise sales model to hospital NICUs following regulatory approval; pricing has not been publicly disclosed and no commercial sales have yet begun. The company is funded by a €2.1 million seed round closed in November 2023, co-led by Furthr VC and Atlantic Bridge with participation from the HBAN MedTech Syndicate and Enterprise Ireland, alongside earlier support from an Enterprise Ireland Commercialisation Fund. The team currently comprises 6 leadership members plus engineers across firmware, software, data science, and QA, with a stated plan to grow to 12 employees by 2025 ahead of its first commercial launch.

Name

Neurobell

Legal name

NeuroBell Ltd.

Website

https://neurobell.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroBell Ltd. is an Irish medical device spin-out from University College Cork developing NeuroBell Luna, a portable AI-powered EEG monitor with automated neonatal seizure detection for use in hospital NICUs, currently in clinical validation ahead of regulatory clearance.

Ownership category

akta.pro rank

Headquarters

HQ city

Cork

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales (Luna): Sale of NeuroBell Luna, a portable EEG monitoring device with AI-powered seizure detection for neonatal ICUs. Product is currently undergoing clinical validation prior to regulatory submissions and is not yet commercially available in EU or US.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

NeuroBell develops Luna, a portable, pocket-sized, wireless 8-channel EEG monitor with AI-powered automated seizure detection for use in neonatal ICUs. The device is battery-powered, WiFi-enabled, compliant with ACNS and 10-20 EEG placement for neonates, and features a two-button setup process for NICU staff. It integrates deep-learning automated seizure detection with cloud-based EEG data review and storage, providing bedside decision support.

Product overview

Neurobell offers a single unified product, NeuroBell Luna, which is a portable brain monitoring device designed specifically for neonatal seizure detection. The device combines hardware (pocket-sized wireless EEG monitor) with AI-powered software (automated seizure detection via machine learning) and cloud connectivity for data review and storage. The product is currently undergoing clinical validation prior to regulatory submissions and is not yet available for commercial sale in the EU or US.

Differentiator

Problem solved

Functional benefit

Brands

• NeuroBell Luna: Portable brain monitor with AI-powered seizure detection for neonatal ICUs

Products and services

• NeuroBell Luna A portable, pocket-sized, wireless 8-channel EEG monitor with AI-powered automated seizure detection for use in neonatal intensive care units. Battery-powered and WiFi-enabled, with ACNS-compliant 10-20 EEG placement, a two-button user-friendly setup process for NICU staff, and cloud-based review and storage of EEG data for bedside decision support.

Quantifiable outcome

• 1 in 200 newborns suffer brain injury; seizures are most common manifestation requiring treatment
• +1 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• INFANT Research Centre, UCCcoreStrategic or Co-development PartnerNeuroBell was spun out from University College Cork's internationally-renowned INFANT Research Centre. Technology and IP developed through research at this centre since 2015.
• Cork University Hospital (CUH)coreStrategic or Co-development PartnerClinical validation partner for NeuroBell Luna development in EU.
• Parkview HealthcoreStrategic or Co-development PartnerUS clinical validation partner for NeuroBell Luna. Partnership established June 2023.
• Texas Children's HospitalcoreStrategic or Co-development PartnerUS clinical validation partner for NeuroBell Luna development.
• University College CorkcoreStrategic or Co-development PartnerNeuroBell is a spin-out from UCC. The university provides ongoing research collaboration and support through the INFANT Research Centre.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Ceribell: Ceribell develops AI-powered point-of-care EEG systems for seizure detection in hospital settings. It is the most direct comparable to NeuroBell Luna, sharing the AI/portable/cloud strategy and targeting rapid bedside brain monitoring without requiring neurophysiologists.
• Compumedics: Compumedics manufactures clinical EEG equipment and AI-supported sleep/neurology diagnostics. It is comparable to NeuroBell's EEG hardware-and-software approach, though primarily focused on adult and sleep applications rather than neonatal seizure detection.
• ANT Neuro: ANT Neuro produces EEG hardware and software used in clinical and research neurophysiology. It is a direct comparable in EEG device manufacturing and is increasingly investing in AI-assisted EEG interpretation, though its positioning skews more toward research and adult neurology than neonatal ICU.

Broad incumbents

• Natus Medical: Natus is an established manufacturer of EEG, neurodiagnostic, and newborn care equipment used in NICUs worldwide. It competes with NeuroBell in neonatal EEG monitoring but as part of a much broader neurology and newborn-care portfolio rather than a focused AI seizure-detection niche.
• Nihon Kohden: Nihon Kohden is a global leader in patient monitoring and neurodiagnostic EEG systems used in ICUs. It overlaps with NeuroBell in NICU brain monitoring but competes as a full-line patient monitoring incumbent, not a neonatal-specific AI specialist.
• Masimo: Masimo is a major patient-monitoring company with brain-monitoring and ICU sedation-depth products. Its hospital salesforce, ICU footprint, and SedLine/Patient SafetyNet offerings position it as a broad incumbent that NeuroBell could displace or partner with in NICU settings.
• Medtronic: Medtronic is a diversified medical device leader with neurology and patient-monitoring businesses. It is relevant as a broad incumbent that competes for ICU capital budgets and could potentially acquire NeuroBell or partner to extend EEG/AI capabilities into its NICU offering.

Emerging players

• Empatica: Empatica builds wearable devices with AI-based seizure detection algorithms. It targets similar AI/seizure-detection capabilities as NeuroBell but via consumer wearables rather than NICU-grade clinical EEG, making it an adjacent emerging player rather than a direct competitor.
• Wave Neuroscience: Wave Neuroscience (and similar emerging AI-EEG analytics firms) brings AI-driven EEG interpretation to neurology workflows. It is comparable to NeuroBell's machine-learning seizure detection layer but generally serves outpatient and research neurology rather than acute neonatal care.
• iCE Neurosystems: iCE Neurosystems provides continuous EEG monitoring and AI analytics for hospital ICUs. It targets a closely overlapping use case (continuous ICU brain monitoring with decision support) and is an emerging-play alternative path to the same clinical problem NeuroBell addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/neurobell_
• LinkedInlinkedin.com/company/neurobell

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurobell